

## S05-7 DRUG RE-PROFILING (discovery of new efficacy from the current drug)

○Masakatsu IMOTO<sup>1</sup>

<sup>1</sup>Ministry of Health, Labour and Welfare

---

Development of the drug is generally said that the plenty of money are needed. The pharmaceutical development cost will reflect in the medicine charge. To reduce the cost will be expected to reduce not only the risk of the development, but also load of the medical care on nation. A great development risk lets venture capital hesitate to supply risk money to venture company, and, as a result, it is one of the obstacles of the medical development activity. As for Drug Re-Profiling, it has many merits than the development from early stage of a non-clinical test because there are already the clinical use data. On the other hand, the multifunctional drugs mean to show side effect except the intended effect. In addition, there are many the problems of the development entry by the company which does not have a material patent.